GlaxoSmithKline (GSK) has signed an agreement to help make up to 60 million doses of Novavax’s COVID-19 vaccine NVX-CoV2373 in the UK. The agreement between GSK, Novavax and the UK Vaccines Taskforce ...

Regulators in the United Kingdom have approved full marketing authorization for Gaithersburg-based Novavax’s updated, protein-based COVID-19 booster shot, but regulators in the European Union have ...

Novavax will refund $123.8 million to the UK agency in quarterly payments of $10.3 million over three years. The two parties initially entered into a COVID-19 vaccine supply deal in 2020. Get access ...

Gaithersburg, Maryland-based Novavax has filed for approval for use of its COVID-19 vaccine in teenagers in the U.K. The application, with the Medicines and Healthcare Products Regulatory Agency of ...

A new Covid-19 vaccine from Novavax was 89% effective and appeared to offer protection against some variants of the coronavirus in a clinical trial conducted in the UK, the American biotech firm has ...

(RTTNews) - Novavax, Inc. (NVAX), a vaccine maker focused on serious infectious diseases, said on Tuesday that an initial one million doses of Nuvaxovid or NVX-CoV2373 Covid-19 vaccine are now ready ...

Novavax says its COVID-19 vaccine appears 89% effective, based on early findings from a British study. According to USA Today, the two-dose vaccine was just 60% effective in the South African trial.

Novavax (NVAX) closed at $86.55 in the latest trading session, marking a -0.67% move from the prior day. This change lagged the S&P 500's 0.09% gain on the day. Elsewhere, the Dow lost 0.16%, while ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax, Inc. stock has been facing a downward spiral, but there may be a short-term trading opportunity if FDA approval for its COVID-19 vaccine is positive. The high level of short interest in ...

Novavax released its FY22 earnings last week. The news was not good. Although the company did make product sales of $1.6bn, it made a substantial loss of >$650, after a >$1.7bn loss in the prior year.

Novavax Inc. said Thursday that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not quite as well — against new mutated ...